Top

16-10-2018 | Psoriatic arthritis | Review | Article

Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review

Journal: Clinical Rheumatology

Authors: Maxime Sondag, Frank Verhoeven, Xavier Guillot, Clément Prati, Daniel Wendling

Publisher: Springer London

Abstract

Dactylitis is a frequent disabling feature of psoriatic arthritis (PsA). Therapeutic strategy on dactylitis is not really codified. We performed a complementary literature review (since a previous one in 2014) of efficacy of new treatments recently used in PsA on this specific clinical manifestation. Eleven publications were retained (4697 patients). In the randomized double-blind placebo-controlled trials analyzed, authors declared ustekinumab, ixekizumab, adalimumab, and apremilast efficient. Secukinumab, clazakizumab, abatacept, and tofacitinib were promising. Brodalumab was ineffective. Calculations of odds ratios for residual dactylitis were significant for clazakizumab 100 mg and secukinumab in anti-TNF-naïve population. Homogenization of dactylitis assessment and use of this criterion as primary outcome are necessary to have better data on treatment efficacy in the future.

Yamamoto T (2015) Optimal management of dactylitis in patients with psoriatic arthritis. Open Access Rheumatol Res Rev 7:55–62. https://doi.org/10.2147/OARRR.S60821 CrossRef

Baranauskaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N, RESPOND investigators (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71:541–548. https://doi.org/10.1136/ard.2011.152223 CrossRefPubMed

Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V (2013) Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol 40:1357–1359. https://doi.org/10.3899/jrheum.130163 CrossRefPubMed

Rose S, Toloza S, Bautista-Molano W, Helliwell PS, on behalf of the GRAPPA Dactylitis Study Group, Adebajo A, Carneiro S, Haddad A, Kaeley G, Kafka S, Moverley A, Nadashkevich O, Parkinson A, Queiro R, Schainberg C, Ucar U, Valle-Onate R, Zmierczak HG (2014) Comprehensive treatment of dactylitis in psoriatic arthritis. J Rheumatol 41:2295–2300. https://doi.org/10.3899/jrheum.140879 CrossRefPubMed

Ramiro S, Smolen JS, Landewé R, van der Heijde D, Dougados M, Emery P, de Wit M, Cutolo M, Oliver S, Gossec L (2016) Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 75:490–498. https://doi.org/10.1136/annrheumdis-2015-208466 CrossRefPubMed

Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2017) Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol Hoboken NJ 69:2151–2161. https://doi.org/10.1002/art.40226 CrossRef

Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB (2016) Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis 75:1984–1988. https://doi.org/10.1136/annrheumdis-2015-209068 CrossRefPubMed

Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75:1065–1073. https://doi.org/10.1136/annrheumdis-2015-207963 CrossRefPubMedPubMedCentral

Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD, SPIRIT-P1 Study Group (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79–87. https://doi.org/10.1136/annrheumdis-2016-209709 CrossRefPubMed

10.

McInnes IB, Mease PJ, Kirkham B et al (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl 386:1137–1146. https://doi.org/10.1016/S0140-6736(15)61134-5 CrossRef

11.

Kavanaugh A, McInnes IB, Mease PJ et al (2016) Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 43:1713–1717. https://doi.org/10.3899/jrheum.160275 CrossRefPubMed

12.

Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S (2016) The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol Hoboken NJ 68:2163–2173. https://doi.org/10.1002/art.39700 CrossRef

13.

Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525–1536. https://doi.org/10.1056/NEJMoa1615977 CrossRefPubMed

14.

Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377:1537–1550. https://doi.org/10.1056/NEJMoa1615975 CrossRefPubMed

15.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76:1550–1558. https://doi.org/10.1136/annrheumdis-2016-210724 CrossRefPubMedPubMedCentral

16.

Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng JY, Erondu N, Nirula A (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370:2295–2306. https://doi.org/10.1056/NEJMoa1315231 CrossRefPubMed

17.

Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE (2005) Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 32:1745–1750PubMed

18.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu CC, Hough D, Stevens RM, Schett G (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026. https://doi.org/10.1136/annrheumdis-2013-205056 CrossRefPubMedPubMedCentral

19.

Carron P, Varkas G, Cypers H, van Praet L, Elewaut D, van den Bosch F, CRESPA investigator group (2017) Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study. Ann Rheum Dis 76:1389–1395. https://doi.org/10.1136/annrheumdis-2016-210775 CrossRefPubMed

20.

Mease P, Sieper J, Van den Bosch F et al (2015) Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol Hoboken NJ 67:914–923. https://doi.org/10.1002/art.39008 CrossRef

21.

Coates LC, Helliwell PS (2016) Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol 43:356–361. https://doi.org/10.3899/jrheum.150614 CrossRefPubMed

22.

Healy PJ, Helliwell PS (2007) Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 34:1302–1306PubMed

23.

Feletar M, Hall S, Bird P (2016) Evaluation of magnetic resonance imaging responsiveness in active psoriatic arthritis at multiple timepoints during the first 12 weeks of antitumor necrosis factor therapy. J Rheumatol 43:75–80. https://doi.org/10.3899/jrheum.150347 CrossRefPubMed

24.

Vieira-Sousa E, Alves P (2015) Dactylitis: more than just arthritis. Acta Reumatol Port 40:210–212PubMed

25.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol Hoboken NJ 68:1060–1071. https://doi.org/10.1002/art.39573 CrossRef

Medicine Matters Rheumatology

Abstract